Abstract
The novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has caused a pandemic resulting in over 2.7 million infected individuals and over 190,000 deaths and growing. Respiratory disorders in COVID-19 caused by the virus commonly present as viral pneumonia-like opacities in chest X-ray images which are used as an adjunct to the reverse transcription-polymerase chain reaction test for confirmation and evaluating disease progression. The surge places high demand on medical services including radiology expertise. However, there is a dearth of sufficient training data for developing image-based automated decision support tools to alleviate radiological burden. We address this insufficiency by expanding training data distribution through use of weakly-labeled images pooled from publicly available CXR collections showing pneumonia-related opacities. We use the images in a stage-wise, strategic approach and train convolutional neural network-based algorithms to detect COVID-19 infections in CXRs. It is observed that weakly-labeled data augmentation improves performance with the baseline test data compared to non-augmented training by expanding the learned feature space to encompass variability in the unseen test distribution to enhance inter-class discrimination, reduce intra-class similarity and generalization error. Augmentation with COVID-19 CXRs from individual collections significantly improves performance compared to baseline non-augmented training and weakly-labeled augmentation toward detecting COVID-19 like viral pneumonia in the publicly available COVID-19 CXR collections. This underscores the fact that COVID-19 CXRs have a distinct pattern and hence distribution, unlike non-COVID-19 viral pneumonia and other infectious agents.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Intramural Research Program of the Lister Hill National Center for Biomedical Communications (LHNCBC), the National Library of Medicine (NLM), and the U.S. National Institutes of Health (NIH).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The study uses publicly available datasets, the detailed are mentioned in the manuscript.